Lung Cancer

The phase 3 ADAURA trial continues to generate a lot conversation, debate, and excitement in the lung cancer community after results showed that adjuvant osimertinib showed a statistically significant improvement in disease-free survival in patients with stage IB-IIIA EGFR-positive non–small cell lung cancer, making it the first agent to do so in the space.

Treatment with afatinib followed by osimertinib resulted in a median overall survival benefit of almost 4 years in US patients with EGFR T790M–positive non–small cell lung cancer in the real-world setting.

In a special OncLive video program, The Board, Joshua M. Bauml, MD, led a discussion regarding key abstracts that were presented during the 2020 ASCO Virtual Scientific Program in non–small cell lung cancer .

The anti–PD-L1 monoclonal antibody CS1001 in combination with platinum-based chemotherapy led to a significant improvement in progression-free survival when used as a frontline treatment for patients with stage IV squamous and nonsquamous non–small cell lung cancer.

Paul A. Bunn, Jr, MD, discusses antibody-drug conjugates and how they are on the cusp of being introduced into the treatment paradigm for patients with HER2-mutant non–small cell lung cancer.

Nivolumab plus ipilimumab significantly improved overall survival versus chemotherapy in the first-line treatment of patients with unresectable malignant pleural mesothelioma.

Ensartinib showed a significant improvement in progression-free survival over crizotinib with a favorable safety profile in patients with ALK-positive non–small cell lung cancer.

Sintilimab injection plus pemetrexed and platinum-based therapy led to a statistically significant improvement in progression-free survival compared with chemotherapy alone as a first-line treatment for patients with locally advanced or metastatic nonsquamous non–small cell lung cancer.

Anne Chiang, MD, PhD, discusses the rationale for combining immunotherapy with chemotherapy in lung cancer.